AutoGenomics has developed the automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics.

With the discovery of genes and their link to various disease states, the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine.

Robert Cole, chief medical officer of AutoGenomics, said: “We congratulate Plexxikon and Roche on the dramatic success of their compound PLX-4032, a treatment for melanoma and other cancers harboring the V600E mutation of the B-RAF kinase gene.”

Melanoma is the type of skin cancer with about 70,000 new melanoma cases diagnosed every year in the US and about 160,000 worldwide. When diagnosed, early melanoma is curable, however advanced stage disease has carried a poor prognosis up to now.